Autopsy report · NCT02698189

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)

“This study was terminated due to limited efficacy and not due to safety reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 5 years 4 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

AML Including AML de Novo and AML Secondary to MDS; DLBCL

Interventions

Birabresib Dose 20 mg

Participants

9

Trials that died the same way

• Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
  “This study was terminated for reasons not related to efficacy or safety” (97% match in meaning)
• A Study of Tadalafil for Duchenne Muscular Dystrophy
  “The study is being terminated for lack of efficacy” (89% match in meaning)
• Dasatinib in Polycythemia Vera
  “This study was terminated due to lack of efficacy.” (88% match in meaning)
• Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
  “The study was terminated due to lack of efficacy.” (87% match in meaning)
• A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
  “This study was terminated due to a lack of efficacy.” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.